RU2250102C2 - Способ доставки биологически активного соединения на ассоциированную со слизистой оболочкой лимфоретикулярную ткань животного, способ получения композиции и композиция для доставки биологически активного соединения - Google Patents

Способ доставки биологически активного соединения на ассоциированную со слизистой оболочкой лимфоретикулярную ткань животного, способ получения композиции и композиция для доставки биологически активного соединения Download PDF

Info

Publication number
RU2250102C2
RU2250102C2 RU98121515/15A RU98121515A RU2250102C2 RU 2250102 C2 RU2250102 C2 RU 2250102C2 RU 98121515/15 A RU98121515/15 A RU 98121515/15A RU 98121515 A RU98121515 A RU 98121515A RU 2250102 C2 RU2250102 C2 RU 2250102C2
Authority
RU
Russia
Prior art keywords
microcapsules
antigen
microns
size
biologically active
Prior art date
Application number
RU98121515/15A
Other languages
English (en)
Russian (ru)
Inventor
Томас Р. ТАЙС (US)
Томас Р. Тайс
Ричард М. ДЖИЛЛИ (US)
Ричард М. ДЖИЛЛИ
Джон Х. ЭЛДРИДЖ (US)
Джон Х. ЭЛДРИДЖ
Джей К. СТАСС (US)
Джей К. СТАСС
Original Assignee
Саутерн Рисерч Инститьют
Дзе Ю Эй Би Рисерч Фаундейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22617981&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2250102(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Саутерн Рисерч Инститьют, Дзе Ю Эй Би Рисерч Фаундейшн filed Critical Саутерн Рисерч Инститьют
Application granted granted Critical
Publication of RU2250102C2 publication Critical patent/RU2250102C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y10T428/2985—Solid-walled microcapsule from synthetic polymer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2989—Microcapsule with solid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Vending Machines For Individual Products (AREA)
  • Electrotherapy Devices (AREA)
RU98121515/15A 1988-03-18 1989-03-16 Способ доставки биологически активного соединения на ассоциированную со слизистой оболочкой лимфоретикулярную ткань животного, способ получения композиции и композиция для доставки биологически активного соединения RU2250102C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US169973 1988-03-18
US07/169,973 US5075109A (en) 1986-10-24 1988-03-18 Method of potentiating an immune response

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2005104392/15A Division RU2005104392A (ru) 1988-03-18 2005-02-17 Композиции для стимулирования или усиления иммунного ответа и их применение

Publications (1)

Publication Number Publication Date
RU2250102C2 true RU2250102C2 (ru) 2005-04-20

Family

ID=22617981

Family Applications (3)

Application Number Title Priority Date Filing Date
RU98121515/15A RU2250102C2 (ru) 1988-03-18 1989-03-16 Способ доставки биологически активного соединения на ассоциированную со слизистой оболочкой лимфоретикулярную ткань животного, способ получения композиции и композиция для доставки биологически активного соединения
SU4831769A RU2127118C1 (ru) 1988-03-18 1989-03-16 Способ доставки биоактивного агента животному для инициации иммунного ответа (варианты)
RU2005104392/15A RU2005104392A (ru) 1988-03-18 2005-02-17 Композиции для стимулирования или усиления иммунного ответа и их применение

Family Applications After (2)

Application Number Title Priority Date Filing Date
SU4831769A RU2127118C1 (ru) 1988-03-18 1989-03-16 Способ доставки биоактивного агента животному для инициации иммунного ответа (варианты)
RU2005104392/15A RU2005104392A (ru) 1988-03-18 2005-02-17 Композиции для стимулирования или усиления иммунного ответа и их применение

Country Status (20)

Country Link
US (1) US5075109A (Direct)
EP (3) EP0333523B1 (Direct)
JP (1) JP2521827B2 (Direct)
KR (1) KR0126823B1 (Direct)
CN (3) CN1211080C (Direct)
AT (2) ATE140386T1 (Direct)
AU (1) AU633483B2 (Direct)
CA (1) CA1340692C (Direct)
DE (2) DE68929499T2 (Direct)
DK (1) DK175851B1 (Direct)
ES (2) ES2088890T3 (Direct)
GR (1) GR3020569T3 (Direct)
HK (1) HK38897A (Direct)
IE (1) IE83868B1 (Direct)
IL (1) IL89602A (Direct)
IN (1) IN169330B (Direct)
NZ (1) NZ228376A (Direct)
RU (3) RU2250102C2 (Direct)
WO (1) WO1989008449A1 (Direct)
ZA (1) ZA892103B (Direct)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE112006004066T5 (de) 2006-10-13 2009-08-20 Aleksandr Mettalinovich Tishin Magnetischer Träger und medizinisches Präparat zur kontrollierbaren Zuführung und Freisetzung von Wirkstoffen, Herstellungsverfahren dafür und Behandlungsverfahren unter Verwendung davon

Families Citing this family (659)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US6217911B1 (en) 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
US6410056B1 (en) 1984-03-16 2002-06-25 The United States Of America As Represented By The Secretary Of The Army Chemotherapeutic treatment of bacterial infections with an antibiotic encapsulated within a biodegradable polymeric matrix
US5693343A (en) 1984-03-16 1997-12-02 The United States Of America As Represented By The Secretary Of The Army Microparticle carriers of maximal uptake capacity by both M cells and non-M cells
USRE40786E1 (en) 1984-03-16 2009-06-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres
NZ217821A (en) * 1985-10-10 1989-07-27 Biotech Australia Pty Ltd Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
US5811128A (en) * 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US5807832A (en) * 1987-06-09 1998-09-15 Biotech Australia Pty Limited Oral delivery of biologically active substances bound to vitamin B12
US5116612A (en) * 1987-06-23 1992-05-26 Allergy Immuno Technologies, Inc. Immunotherapy agents for treatment of IgE mediated allergies
AU639903B2 (en) * 1989-01-20 1993-08-12 University Of Melbourne, The Fibrinolysis
US5236705A (en) * 1989-01-20 1993-08-17 The University Of Melbourne Fibrinolysis
US4990336A (en) * 1989-02-08 1991-02-05 Biosearch, Inc. Sustained release dosage form
WO1990013361A1 (en) * 1989-05-04 1990-11-15 Southern Research Institute Improved encapsulation process and products therefrom
US6126945A (en) * 1989-10-03 2000-10-03 Pharmacia Ab Tumor killing effects of enterotoxins, superantigens, and related compounds
DK546289D0 (da) * 1989-11-02 1989-11-02 Danochemo As Carotenoidpulvere
JP2571874B2 (ja) * 1989-11-06 1997-01-16 アルカーメス コントロールド セラピューティクス，インコーポレイテッド タンパク質マイクロスフェア組成物
SG46225A1 (en) * 1990-04-24 1998-02-20 Flustat Pty Limited Oral vaccine comprising antigen surface-associated with red blood cells
US5882649A (en) * 1990-04-24 1999-03-16 Flustat Pty. Ltd. Oral vaccine comprising antigen surface-associated with red blood cells
DK0462305T3 (da) * 1990-06-21 1995-04-24 Huland Edith Anvendelse af cytokinholdige aerosoler såvel som cytokholdige aerosoler i sig selv
US5780012A (en) * 1990-06-21 1998-07-14 Huland; Edith Method for reducing lung afflictions by inhalation of cytokine solutions
US6159502A (en) * 1991-04-02 2000-12-12 Biotech Australia Pty Ltd Oral delivery systems for microparticles
WO1992019263A1 (en) 1991-04-24 1992-11-12 The United States Of America, As Represented By The Secretary Of The Army Oral-intestinal vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US5283066A (en) * 1992-02-19 1994-02-01 Development Center For Biotechnology Method of stimulating an immune response by using a hapten
US5352461A (en) * 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
US6197346B1 (en) 1992-04-24 2001-03-06 Brown Universtiy Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US6235313B1 (en) 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US5922340A (en) 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
ATE210969T1 (de) * 1992-09-10 2002-01-15 Childrens Medical Center Biodegradierbare polymeren matrizen mit verzoegerter freisetzung von lokalanaesthetika
US5700485A (en) 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
WO1994007469A1 (en) * 1992-09-25 1994-04-14 Dynagen, Inc. An immunobooster for delayed release of immunogen
EP0646000A4 (en) * 1992-11-16 1997-05-02 Univ Mercer COMPOSITIONS CONTAINING MICRO-ENCODED NEUTRALIZING ANTIBODIES.
DE69305313T3 (de) * 1992-12-22 2001-06-21 The University Of Cincinnati, Cincinnati Orale Verabreichung von immunologischen aktiven Biomolekülen und anderen therapeutischen Proteinen
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6939546B2 (en) 1993-05-21 2005-09-06 The United States Of America As Represented By The Secretary Of The Army Model for testing immunogenicity of peptides
US5603960A (en) * 1993-05-25 1997-02-18 O'hagan; Derek T. Preparation of microparticles and method of immunization
US5562909A (en) * 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
US6004534A (en) * 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
WO1995003035A1 (en) * 1993-07-23 1995-02-02 Massachusetts Institute Of Technology Polymerized liposomes with enhanced stability for oral delivery
ATE223702T1 (de) * 1993-10-22 2002-09-15 Genentech Inc Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien
JP3841309B2 (ja) * 1993-10-22 2006-11-01 ジェネンテック・インコーポレーテッド 流動床乾燥工程を含んでなるミクロスフェアの製造方法
EP0724432B1 (en) * 1993-10-22 2002-09-18 Genentech, Inc. Methods and compositions for microencapsulation of antigens for use as vaccines
US5643605A (en) * 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
US6080429A (en) * 1993-10-25 2000-06-27 Genentech, Inc. Method for drying microspheres
US6913767B1 (en) 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
ATE288270T1 (de) * 1993-11-19 2005-02-15 Janssen Pharmaceutica Nv Mikroverkapselte 1,2-benzazole
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
US6531156B1 (en) 1994-04-15 2003-03-11 Temple University Aqueous solven encapsulation method, apparatus and microcapsules
US5876735A (en) * 1994-04-22 1999-03-02 Corixa Corporation Methods for enhancement of protective immune responses
US6013268A (en) 1994-04-22 2000-01-11 Corixa Corporation Methods for enhancement of protective immune responses
US6855331B2 (en) 1994-05-16 2005-02-15 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US5571531A (en) * 1994-05-18 1996-11-05 Mcmaster University Microparticle delivery system with a functionalized silicone bonded to the matrix
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US5681819A (en) * 1994-12-01 1997-10-28 Oklahoma Medical Research Foundation Method and compositions for reducing cholesterol absorption
US5821226A (en) * 1994-12-01 1998-10-13 Oklahoma Medical Research Foundation BAL C-tail drug delivery molecules
US5696087A (en) * 1994-12-01 1997-12-09 Oklahoma Medical Research Foundation Method and compositions for reducing cholesterol absorption
US6902743B1 (en) 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US7033608B1 (en) 1995-05-22 2006-04-25 The United States Of America As Represented By The Secretary Of The Army “Burst-free” sustained release poly-(lactide/glycolide) microspheres
WO1996041616A1 (en) 1995-06-09 1996-12-27 Euro-Celtique, S.A. Formulations and methods for providing prolonged local anesthesia
EP0840623B1 (en) 1995-07-21 2007-07-18 Brown University Research Foundation Compositions for gene therapy comprising nucleic acid loaded polymeric microparticles
US6248720B1 (en) 1996-07-03 2001-06-19 Brown University Research Foundation Method for gene therapy using nucleic acid loaded polymeric microparticles
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
DE69636487T2 (de) 1995-09-01 2007-05-03 Corixa Corp. CSC, Wilmington Zusammensetzungen zur Immuntherapie und Diagnose von Tuberculosis
DE69608122T3 (de) † 1995-11-09 2011-06-16 Microbiological Research Authority Camr, Salisbury Mikroverkapselte dna zur impfung und gentherapie
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
US5985312A (en) * 1996-01-26 1999-11-16 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
US6368586B1 (en) 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
US6342218B1 (en) 1997-02-14 2002-01-29 Oklahoma Medical Research Foundation Method for treatment of SLE
US6207185B1 (en) 1996-03-22 2001-03-27 Bio-Sphere Technology Method for inducing a systemic immune response to an HIV antigen
US6117449A (en) * 1996-03-22 2000-09-12 Bio-Sphere Technology, Inc. Method for inducing a systemic immune response to a hepatitis antigen
US6015576A (en) * 1997-08-29 2000-01-18 Bio-Sphere Technology, Inc. Method for inducing a systemic immune response to an antigen
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US20020052310A1 (en) 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
US6652837B1 (en) 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
CA2260750C (en) 1996-06-24 2004-11-09 Euro-Celtique, S.A. Methods for providing safe local anesthesia
US5955096A (en) * 1996-06-25 1999-09-21 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
US6344202B1 (en) * 1996-07-12 2002-02-05 University Of Manitoba DNA immunization against chlaymdia infection
US5980948A (en) * 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
US6046187A (en) 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
PT1005374E (pt) * 1997-01-22 2007-07-18 Mgi Pharma Biolog Inc Micropartículas para administração de ácido nucleico
EP0981624A2 (en) 1997-02-12 2000-03-01 Corixa Corporation $i(LEISHMANIA) ANTIGENS FOR USE IN THE THERAPY AND DIAGNOSIS OF LEISHMANIASIS
US6261562B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
ES2374621T3 (es) 1997-04-02 2012-02-20 The Brigham And Women's Hospital, Inc. Medios para evaluar el perfil de riesgo de un individuo de sufrir una enfermedad ateroesclerótica.
ZA982968B (en) 1997-04-09 1998-10-27 Corixa Corp Compositions and methods for the treatment and diagnosis of breast cancer
US6060082A (en) * 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
IL129951A0 (en) 1997-07-02 2000-02-29 Euro Celtique Sa Prolonged anesthesia in joints and body spaces
AU760034B2 (en) * 1997-08-29 2003-05-08 Corixa Corporation Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof
EP1579851A3 (en) * 1997-08-29 2009-09-02 Corixa Corporation Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of use thereof
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6197229B1 (en) * 1997-12-12 2001-03-06 Massachusetts Institute Of Technology Method for high supercoiled DNA content microspheres
CA2314934C (en) * 1997-12-16 2006-08-29 Chiron Corporation Use of microparticles combined with submicron oil-in-water emulsions
US7393630B2 (en) 1997-12-16 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Use of microparticles combined with submicron oil-in-water emulsions
EP1992640A1 (en) 1997-12-24 2008-11-19 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
KR20010041992A (ko) 1998-03-18 2001-05-25 길리스 스티브 폐암의 치료와 진단을 위한 화합물 및 이를 위한 방법
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
BR9909472A (pt) 1998-04-07 2001-09-11 Corixa Corp Polipeptìdeo purificado, processo para prevenir tuberculose, e, composição farmacêutica
AU3555599A (en) 1998-04-13 1999-11-01 Luminex Corporation Liquid labeling with fluorescent microparticles
SE9801288D0 (sv) 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and metod of production
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
DK1077722T3 (da) 1998-05-22 2006-11-27 Ottawa Health Research Inst Fremgangsmåder og produkter til induktion af mukosaimmunitet
JP2002518349A (ja) 1998-06-18 2002-06-25 ジョンズ ホプキンス ユニバーシティ スクール オブ メディシン 核酸デリバリー用ポリマー
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
TR200100373T2 (tr) 1998-08-07 2001-09-21 University Of Washington İmünolojik uçuk virüsü antijenleri ve bunların kullanım yöntemleri
US6264991B1 (en) 1998-08-18 2001-07-24 Southern Research Institute Compositions and methods for treating intracellular infections
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US7087236B1 (en) 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
AU5441199A (en) 1998-09-01 2000-03-21 Elan Corporation, Plc Oral vaccine compositions
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
FR2786098B1 (fr) 1998-11-20 2003-05-30 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
DE69942426D1 (de) 1998-12-08 2010-07-08 Corixa Corp Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
DE69939553D1 (de) 1998-12-30 2008-10-23 Beth Israel Hospital Charakterisierung der proteinfamilie von soc/crac kalziumkanälen
US6395714B1 (en) 1999-02-24 2002-05-28 Aventis Pasteur Limited Expressing gp140 fragment of primary HIV-1 isolate
MXPA01009962A (es) 1999-04-02 2002-08-20 Corixa Corp Compuestos y metodos para terapia y diagnostico de cancer de pulmon.
US20050158856A1 (en) * 1999-04-20 2005-07-21 Edelson Richard L. Methods for producing functional antigen presenting dendritic cells using biodegradable microparticles for delivery of antigenic materials
US6521431B1 (en) * 1999-06-22 2003-02-18 Access Pharmaceuticals, Inc. Biodegradable cross-linkers having a polyacid connected to reactive groups for cross-linking polymer filaments
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
JP4210454B2 (ja) * 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
US20020009466A1 (en) * 1999-08-31 2002-01-24 David J. Brayden Oral vaccine compositions
AU7574700A (en) 1999-09-03 2001-04-10 Brigham And Women's Hospital Methods and compositions for treatment of inflammatory disease using cadherin-11modulating agents
US6811783B1 (en) * 1999-09-07 2004-11-02 Aventis Pasteur Limited Immunogenic compositions for protection against chlamydial infection
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US20050037086A1 (en) * 1999-11-19 2005-02-17 Zycos Inc., A Delaware Corporation Continuous-flow method for preparing microparticles
FR2801226B1 (fr) 1999-11-23 2002-01-25 Flamel Tech Sa Suspension colloidale de particules submicroniques de vectorisation de principes actifs et son mode de preparation
JP5502253B2 (ja) 2000-02-23 2014-05-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規化合物
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
WO2001078709A2 (en) * 2000-04-12 2001-10-25 Minerva Biotechnologies Corporation Treatment of neurodegenerative disease
WO2001081379A2 (en) 2000-04-21 2001-11-01 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
ATE299696T1 (de) 2000-05-12 2005-08-15 Pharmacia & Upjohn Co Llc Impfstoffzusammensetzung und verfahren zur herstellung derselben sowie verfahren zur impfung von wirbeltieren
JP2003535122A (ja) * 2000-06-02 2003-11-25 ザイコス インク． 生物活性物質のための送達システム
FR2814952B1 (fr) 2000-10-06 2004-01-02 Flamel Tech Sa Suspension colloidale de particules submicromiques de vectorisation de principes actifs et leur mode de preparation
ES2374620T3 (es) 2000-06-20 2012-02-20 Corixa Corporation Antígeno mtb32a de mycobacterium tuberculosis con el sitio activo inactivado y proteínas de fusión de los mismos.
EP1296714B1 (en) 2000-06-22 2009-08-26 University Of Iowa Research Foundation Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
WO2002000174A2 (en) 2000-06-28 2002-01-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6565888B1 (en) 2000-08-23 2003-05-20 Alkermes Controlled Therapeutics, Inc. Methods and compositions for the targeted delivery of biologically active agents
US6797704B2 (en) 2000-10-06 2004-09-28 The Johns Hopkins University Systemic delivery of compounds through non-invasive bladder administration
US7374782B2 (en) 2000-10-27 2008-05-20 Baxter International Inc. Production of microspheres
US7700715B2 (en) 2000-11-27 2010-04-20 Minerva Biotechnologies Corporation Diagnostic tumor markers, drug screening for tumorigenesis inhibition, and compositions and methods for treatment of cancer
EP1350262B8 (en) * 2000-12-08 2008-08-13 Coley Pharmaceuticals GmbH Cpg-like nucleic acids and methods of use thereof
JP2005504715A (ja) * 2000-12-29 2005-02-17 アドバンスト インハレーション リサーチ，インコーポレイテッド 持続放出特性を有する吸入用粒子
US20030125236A1 (en) * 2000-12-29 2003-07-03 Advenced Inhalation Research, Inc. Particles for inhalation having rapid release properties
CN1911965B (zh) 2001-01-17 2013-05-29 新兴产品开发西雅图有限公司 结合域-免疫球蛋白融合蛋白
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US7618939B2 (en) * 2001-02-15 2009-11-17 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
CA2446788A1 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP1417236A4 (en) 2001-07-10 2010-03-17 Corixa Corp COMPOSITIONS AND METHODS FOR ADMINISTRATION OF ENCAPSULATED PROTEINS AND ADJUVANTS IN MICROSPHERES
WO2003013683A1 (en) * 2001-08-08 2003-02-20 Brown University Research Foundation Methods for micronization of hydrophobic drugs
WO2003015750A1 (en) * 2001-08-16 2003-02-27 Baxter International, Inc. Propellant-based microparticle formulations
EP1455593B1 (en) 2001-10-06 2013-07-24 Merial Limited Methods and compositions for promoting growth and innate immunity in young animals
JP5232352B2 (ja) 2001-10-10 2013-07-10 ノボ ノルデイスク エイ エス ペプチドの改造および複合糖質化
AU2002340662B2 (en) * 2001-11-07 2008-07-03 Tekmira Pharmaceuticals Corporation Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
CA2467833A1 (en) 2001-11-19 2003-09-04 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
WO2003043603A1 (en) * 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Particulate compositions for improving solubility of poorly soluble agents
US7182961B2 (en) 2001-11-20 2007-02-27 Advanced Inhalation Research, Inc. Particulate compositions for pulmonary delivery
EP1460897A4 (en) * 2001-12-10 2006-09-13 Spherics Inc PROCESSES AND PRODUCTS SUITED TO THE FORMATION AND ISOLATION OF MICROPARTICLES
JP4737586B2 (ja) 2001-12-11 2011-08-03 インスティティ・パスツール 免疫調節不全を含む疾患の治療のためのグラム陽性細菌調製物
EP2224012B1 (en) 2001-12-17 2013-01-30 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
JP2005514393A (ja) 2001-12-19 2005-05-19 ネクター セラピューティクス アミノグリコシドの肺への供給
US7794965B2 (en) 2002-03-13 2010-09-14 Signum Biosciences, Inc. Method of identifying modulators of PP2A methylase
ES2543710T3 (es) 2002-04-04 2015-08-21 Zoetis Belgium S.A. Oligorribonucleótidos inmunoestimulantes que contienen G y U
KR101061351B1 (ko) 2002-04-09 2011-08-31 플라멜 테크놀로지스 활성 성분 마이크로캡슐의 경구 현탁액
CN1668763B (zh) 2002-05-09 2012-05-16 布赖汉姆妇女医院 作为心血管病的标志和治疗靶的il1rl-1
US20040013649A1 (en) * 2002-05-10 2004-01-22 Inex Pharmaceuticals Corporation Cancer vaccines and methods of using the same
US20040009944A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Methylated immunostimulatory oligonucleotides and methods of using the same
FR2840614B1 (fr) 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
EP2316479B8 (en) 2002-07-18 2015-03-18 University of Washington Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments
WO2004035028A1 (fr) * 2002-10-17 2004-04-29 Gosudarstvenny Nauchny Tsentr Virusologii I Biotekhnologii 'vektor' Procede de production d'une forme microencapsulee d'un vaccin viral vivant
EP1556513B1 (en) * 2002-10-21 2010-04-28 Eisai Inc. Compositions and methods for treating human papillomavirus-mediated disease
ZA200503511B (en) 2002-10-29 2006-10-25 Coley Pharmaceutical Group Ltd Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
CA2537263C (en) 2002-11-27 2017-05-30 Minerva Biotechnologies Corporation Techniques and compositions for the diagnosis and treatment of cancer (muc1)
AU2004210936C1 (en) 2003-02-11 2010-12-02 Takeda Pharmaceutical Company Limited Diagnosis and treatment of Multiple Sulfatase Deficiency and other using a Formylglycine Generating Enzyme (FGE)
SI1897548T2 (sl) 2003-02-28 2024-09-30 The Johns Hopkins University Regulacija celic T
US8524899B2 (en) * 2003-03-04 2013-09-03 California Institute Of Technology Alternative heterocycles for DNA recognition
JP2006523211A (ja) 2003-03-14 2006-10-12 ネオス テクノロジーズ インコーポレイテッド 分岐水溶性ポリマーとその複合物
SG155777A1 (en) 2003-04-09 2009-10-29 Neose Technologies Inc Glycopegylation methods and proteins/peptides produced by the methods
WO2004111199A2 (en) 2003-06-12 2004-12-23 University Of Colorado System Technology Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
AU2004262640B2 (en) 2003-06-16 2010-12-23 Ucb Manufacturing, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
DE10329087B4 (de) * 2003-06-27 2014-02-13 Biomedical International R + D Gmbh Antigenhaltige Mikrosphären zur Allergietherapie
US20070092452A1 (en) * 2003-07-18 2007-04-26 Julia Rashba-Step Methods for fabrication, uses, compositions of inhalable spherical particles
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
BRPI0412735A (pt) * 2003-07-18 2006-09-26 Baxter Int métodos para a fabricação, uso e composição de partìculas esféricas pequenas preparadas mediante a separação de fase controlada
EP1646354A4 (en) * 2003-07-22 2010-03-17 Baxter Int SMALL SPHERICAL PARTICLES OF LOW MOLECULAR WEIGHT MOLECULES AND PROCESSES FOR THEIR PREPARATION AND USE
US7663017B2 (en) 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
EP1656555B1 (en) 2003-08-20 2012-03-21 Alere San Diego, Inc. Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential
US20060173171A1 (en) * 2003-08-26 2006-08-03 Bamdad Cynthia C Techniques and compositions for diagnosis and treatment of cancer (muci)
CA2542099A1 (en) * 2003-10-11 2005-04-21 Inex Pharmaceuticals Corporation Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
JP5060134B2 (ja) 2003-12-12 2012-10-31 ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ・アズ リプレゼンテッド バイ ザ セクレタリー・デパートメント オブ ヘルス アンド ヒューマン サービシーズ ヒト細胞傷害性Ｔリンパ球のエピトープ及びそのＭＵＣ−１の非ＶＮＴＲ（ｎｏｎ−ｖａｒｉａｂｌｅｎｕｍｂｅｒｏｆｔａｎｄｅｍｒｅｐｅａｔｓｅｑｕｅｎｃｅ）由来のアゴニストエピトープ
EP2248895B8 (en) 2003-12-19 2016-09-21 Autotelic LLC Combination therapy associating a TGF-beta antagonist with a chemotherapeutic agent
US7452730B2 (en) * 2004-01-16 2008-11-18 California Institute Of Technology DNA-binding polymers
EP1568383A3 (en) 2004-02-27 2005-11-16 Antisense Pharma GmbH Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment
WO2005084712A2 (en) * 2004-02-27 2005-09-15 Antisense Pharma Gmbh Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment
US7063151B2 (en) * 2004-03-05 2006-06-20 Halliburton Energy Services, Inc. Methods of preparing and using coated particulates
ES2415358T3 (es) 2004-04-21 2013-07-25 The Brigham And Women's Hospital, Inc. Péptidos de fijación a la poli-N-acetil glucosamina (PNAG/DPNAG) y procedimientos para el uso de los mismos
US20050239723A1 (en) * 2004-04-27 2005-10-27 Amin Avinash N Compositions and methods useful for treatment of acne
CA2566079A1 (en) 2004-05-12 2005-12-01 Terrence L. Scott Nucleic acid microspheres, production and delivery thereof
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
MXPA06012989A (es) 2004-05-12 2007-06-12 Baxter Int Microesferas de acidos nucleicos, produccion y suministro de las mismas.
EP1753404A1 (en) * 2004-05-12 2007-02-21 Baxter International Inc. Microspheres comprising protein and showing injectability at high concentrations of said agent
CA2567597C (en) 2004-05-25 2014-03-18 Oregon Health And Science University Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors
DK2199801T3 (da) 2004-07-14 2013-08-05 Univ California Biomarkører til tidlig påvisning af ovariecancer
US20060264411A1 (en) * 2005-05-20 2006-11-23 Eldridge Gary R Control of biofilm formation
US20060014285A1 (en) * 2004-07-14 2006-01-19 Eldridge Gary R Methods and compositions for inhibiting biofilms
US7604978B2 (en) * 2004-07-14 2009-10-20 Sequoia Sciences, Inc. Inhibition of biofilm formation
WO2006020060A2 (en) 2004-07-15 2006-02-23 Tetralogic Pharmaceuticals Corporation Iap binding compounds
US7807165B2 (en) 2004-07-30 2010-10-05 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
US9132116B2 (en) * 2004-08-02 2015-09-15 Willowcroft Pharm Inc. Mast cell stabilizers to prevent or treat laminitis
AU2005277384B2 (en) 2004-08-17 2011-11-17 The Johns Hopkins University PDE5 inhibitor compositions and methods for treating cardiac indications
EP2338993B1 (en) * 2004-09-02 2013-06-12 Yale University Regulation of oncogenes by microRNAs
US20080064680A1 (en) * 2004-09-14 2008-03-13 Bamdad Cynthia C Methods for Diagnosis and Treatment of Cancer
EP1797108A1 (en) 2004-09-14 2007-06-20 Gary R. Eldridge Compounds, compositions and methods for controlling biofilms and bacterial infections
RU2419628C2 (ru) * 2004-09-22 2011-05-27 ГлаксоСмитКлайн Байолоджикалз с.а. Иммуногенная композиция для применения в вакцинации против стафилококков
US20080138847A1 (en) * 2004-09-23 2008-06-12 Yigong Shi Bcl-2 family member and BH-3 only proteins for use in development of peptidomimetics
WO2006042192A2 (en) 2004-10-06 2006-04-20 The Brigham And Womens's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
AU2005294129B2 (en) 2004-10-08 2010-12-23 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Modulation of replicative fitness by using less frequently used synonymous codons
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US20060275230A1 (en) 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
KR20070095921A (ko) 2004-12-10 2007-10-01 탈리마 테라퓨틱스 인코포레이티드 조갑 단위의 상태를 치료하기 위한 조성물 및 방법
US8137907B2 (en) * 2005-01-03 2012-03-20 Cold Spring Harbor Laboratory Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
WO2006074467A2 (en) 2005-01-10 2006-07-13 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
US8221804B2 (en) 2005-02-03 2012-07-17 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
EP2500031A3 (en) 2005-02-24 2012-12-26 Joslin Diabetes Center, Inc. Compositions and Methods for Treating Vascular Permeability
KR101317661B1 (ko) 2005-02-25 2013-10-15 테트랄로직 파마슈티칼스 코포레이션 이량체성 ｉａｐ 억제제
US7851189B2 (en) * 2005-03-07 2010-12-14 Boston Scientific Scimed, Inc. Microencapsulated compositions for endoluminal tissue engineering
EP1701165A1 (en) 2005-03-07 2006-09-13 Johannes Dr. Coy Therapeutic and diagnostic uses of TKTL1 and inhibitors and activators thereof
EP1875244B1 (en) * 2005-03-30 2019-01-23 Minerva Biotechnologies Corporation Proliferation of muc1 expressing cells
DK1875244T3 (en) 2005-03-30 2019-04-29 Minerva Biotechnologies Corp Proliferation of MUC1-Expressing Cells
AU2006229968A1 (en) 2005-03-31 2006-10-05 Corixa Corporation Vaccines against Chlamydial infection
US20060228384A1 (en) * 2005-04-06 2006-10-12 Sequoia Sciences, Inc. Control of biofilm with a biofilm inhibitor
EP2386571B1 (en) 2005-04-08 2016-06-01 ratiopharm GmbH Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
WO2006113792A2 (en) 2005-04-19 2006-10-26 Eli Lilly And Company Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease
EP2457926B1 (en) 2005-04-29 2014-09-24 GlaxoSmithKline Biologicals S.A. Novel method for preventing or treating M. tuberculosis infection
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
CA2591586A1 (en) 2005-05-05 2006-11-09 Antisense Pharma Gmbh Dosage of oligonucleotides
US20080193543A1 (en) * 2005-05-17 2008-08-14 Brown University Research Foundation Drug Delivery Formulations For Targeted Delivery
WO2007002528A1 (en) * 2005-06-23 2007-01-04 Yale University Anti-aging micrornas
CN101365714A (zh) 2005-07-01 2009-02-11 福赛特儿童口腔医院 结核抗原的检测分析及疫苗
US20070014739A1 (en) * 2005-07-14 2007-01-18 Eldridge Gary R Compositions and methods for controlling biofilms and bacterial infections
AU2006272713A1 (en) * 2005-07-22 2007-02-01 Y's Therapeutics Co, Ltd. Anti-CD26 antibodies and methods of use thereof
WO2007014278A2 (en) 2005-07-25 2007-02-01 Trubion Pharmaceuticals, Inc. B-cell reduction using cd37-specific and cd20-specific binding molecules
AU2006272497B2 (en) 2005-07-27 2012-07-19 University Of Florida Research Foundation, Inc. Small compounds that correct protein misfolding and uses thereof
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
US20070042428A1 (en) * 2005-08-09 2007-02-22 Stacy Springs Treatment of proliferative disorders
TW201402124A (zh) 2005-08-19 2014-01-16 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
EP1957093B1 (en) 2005-08-29 2017-04-12 SHASHOUA, Victor E. Neuroprotective and neurorestorative methods and compositions
US20080021198A1 (en) * 2005-10-12 2008-01-24 Yigong Shi Modulators of protein phosphatase 2A and PP2A methyl esterase
US8658608B2 (en) * 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
BRPI0618857B1 (pt) 2005-11-25 2022-07-19 Zoetis Belgium S.A Oligonucleotídeo de rna isolado, e método para regular negativamente células reguladoras cd4+ imunossupressoras
US20080280834A1 (en) * 2005-12-01 2008-11-13 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compounds and methods for inhibiting apoptosis
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
WO2007079755A1 (en) * 2006-01-12 2007-07-19 Janus Beierholm Holding Aps Reimmunization and antibody design
US9259463B2 (en) 2006-01-16 2016-02-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Chlamydia vaccine
WO2007109583A2 (en) 2006-03-17 2007-09-27 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject
ES2776100T3 (es) 2006-03-31 2020-07-29 Massachusetts Inst Technology Sistema para el suministro dirigido de agentes terapéuticos
CA2648718A1 (en) 2006-04-07 2007-10-18 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
EP2463306A1 (en) 2006-05-02 2012-06-13 Carviar ApS Method for immunizing an avian species
US10522240B2 (en) 2006-05-03 2019-12-31 Population Bio, Inc. Evaluating genetic disorders
US7702468B2 (en) 2006-05-03 2010-04-20 Population Diagnostics, Inc. Evaluating genetic disorders
NZ596865A (en) 2006-06-12 2013-07-26 Emergent Product Dev Seattle Single-chain multivalent binding proteins with effector function
JP2009541236A (ja) 2006-06-20 2009-11-26 トランジェーヌ、ソシエテ、アノニム 組換えウイルスワクチン
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
EP2049524A2 (en) * 2006-07-24 2009-04-22 Tetralogic Pharmaceuticals Corporation Iap inhibitors
US20100113326A1 (en) * 2006-07-24 2010-05-06 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100143499A1 (en) * 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
MX2009000824A (es) * 2006-07-24 2009-02-04 Tetralogic Pharmaceuticals Cor Antagonistas dimericos de las proteinas inhibidoras de la apoptosis.
CN105168146A (zh) 2006-08-04 2015-12-23 巴克斯特国际公司 预防和/或逆转新发作自身免疫糖尿病的基于微球的组合物
US20080153773A1 (en) * 2006-08-08 2008-06-26 Yigong Shi Modulators of phosphotyrosyl phosphatase activator
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PT2486938T (pt) 2006-09-26 2018-06-12 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
CN101600448B (zh) 2006-10-04 2015-11-25 诺和诺德公司 甘油连接的peg化的糖和糖肽
WO2008147426A2 (en) * 2006-10-04 2008-12-04 The Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
US20100092480A1 (en) * 2006-10-13 2010-04-15 The Trustees Of The University Of Princeton Modulators of protein phosphatase 2a
US7645616B2 (en) * 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
WO2008098165A2 (en) 2007-02-09 2008-08-14 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
WO2008109773A2 (en) * 2007-03-06 2008-09-12 Cornell Research Foundation, Inc. Chronic obstructive pulmonary disease susceptibility and related compositions and methods
WO2008116216A1 (en) * 2007-03-22 2008-09-25 Medical College Of Georgia Research Institute, Inc. Compositions and methods for inhibiting cancer metastasis
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
WO2008122039A2 (en) * 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
EP2144600A4 (en) 2007-04-04 2011-03-16 Massachusetts Inst Technology POLY (AMINIC ACID) TARGET MOLECULES
ES2547016T3 (es) 2007-04-12 2015-09-30 The Brigham And Women's Hospital, Inc. Direccionamiento de ABCB5 para terapia para el cáncer
WO2008131129A2 (en) 2007-04-17 2008-10-30 Baxter International Inc. Nucleic acid microparticles for pulmonary delivery
US20100179158A1 (en) * 2007-04-20 2010-07-15 Hoffman Charles S Inhibitors of cyclic amp phosphodiesterases
US8747872B2 (en) * 2007-05-02 2014-06-10 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
EP2160199A2 (en) * 2007-05-17 2010-03-10 Coley Pharmaceutical Group, Inc. Class a oligonucleotides with immunostimulatory potency
EP2166844A4 (en) * 2007-06-07 2013-09-04 Evonik Corp DOSAGE FORMS WITH EXTENDED ACTION AND REDUCED MASS
EP2559773B1 (en) 2007-06-08 2015-04-22 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Methods for determining a hepatocellular carcinoma subtype
EP2591787A1 (en) 2007-08-13 2013-05-15 Pfizer Inc Combination motif immune stimulatory oligonucleotides with improved activity
US8932558B2 (en) * 2007-10-05 2015-01-13 Plaxgen Inc Multi-subunit biological complexes for treatment of plaque-associated diseases
ES2627233T3 (es) 2007-10-12 2017-07-27 Massachusetts Institute Of Technology Nanotecnología de vacunas
US8619257B2 (en) 2007-12-13 2013-12-31 Kimberley-Clark Worldwide, Inc. Recombinant bacteriophage for detection of nosocomial infection
US20090274682A1 (en) * 2008-02-05 2009-11-05 The Trustees Of Princeton University Demethylation and inactivation of protein phosphatase 2a
US20090233858A1 (en) * 2008-02-26 2009-09-17 The Trustees Of Princeton University Structure of a protein phosphatase 2a holoenzyme: insights into tau dephosphorylation
US20090220589A1 (en) * 2008-03-01 2009-09-03 Abraxis Bioscience, Llc Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas
US20110191868A1 (en) 2008-04-10 2011-08-04 Massachusetts Institute Of Technology Methods for identification and use of agents targeting cancer stem cells
EP2274437B1 (en) 2008-04-10 2015-12-23 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
EP2132228B1 (en) 2008-04-11 2011-06-22 Emergent Product Development Seattle, LLC Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US20100227853A1 (en) * 2008-04-18 2010-09-09 Trustees Of Boston College Inhibitors of cyclic amp phosphodiesterases
MX2010011508A (es) 2008-04-18 2011-05-03 Baxter Int Composicion basada en microesferas para prevenir y/o revertir la nueva presentacion de diabetes autoinmune.
AU2009239655B2 (en) 2008-04-25 2014-05-22 Innate Pharma Improved TLR3 agonist compositions
WO2009137660A2 (en) * 2008-05-07 2009-11-12 Abraxis Bioscience, Llc Enhancement of drug therapy by mirna
EP2123748A1 (en) 2008-05-20 2009-11-25 Institut Pasteur 2'-5'-oligoadenylate synthetase 3 for preventing and treating positive-sense single-stranded rna virus infection
EP2303888B1 (en) 2008-06-12 2015-05-06 President and Fellows of Harvard College Compounds for antimicrobial intervention
EP2318832B1 (en) 2008-07-15 2013-10-09 Academia Sinica Glycan arrays on ptfe-like aluminum coated glass slides and related methods
AU2009274512A1 (en) 2008-07-25 2010-01-28 The Regents Of The University Of Colorado Clip inhibitors and methods of modulating immune function
WO2010017103A2 (en) * 2008-08-04 2010-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Fully human anti-human nkg2d monoclonal antibodies
US8367427B2 (en) 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8323685B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
JP2012503004A (ja) 2008-09-17 2012-02-02 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ阻害剤
EP2331103A1 (en) * 2008-09-22 2011-06-15 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Nuclear factor kappa b pathway inhibitor composition and use of same
EP2344447B1 (en) * 2008-10-08 2016-06-08 Xgene Pharmaceutical Inc Gaba conjugates and methods of use thereof
EP2344632B1 (en) 2008-10-09 2022-12-28 Minerva Biotechnologies Corporation Method for inducing pluripotency in cells
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
EP2356446A4 (en) 2008-11-14 2014-03-19 Brigham & Womens Hospital Therapeutic and diagnostic methods related to cancer stem cells
CA2743904A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
WO2010075303A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
WO2010075417A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Survivin specific t cell receptor for treating cancer
US8309356B2 (en) * 2009-04-01 2012-11-13 Yale University Pseudocomplementary oligonucleotides for targeted gene therapy
EP3406244B1 (en) 2009-04-15 2023-06-07 BMG Pharma S.p.A. Compositions comprising zinc gluconate and taurine for mucosal or dermal disorders
AU2010238723A1 (en) 2009-04-23 2011-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ROR1 antibodies
US8686016B2 (en) 2009-04-30 2014-04-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Schweinfurthins and uses thereof
WO2010130374A1 (en) 2009-05-14 2010-11-18 Bayer Animal Health Gmbh Enhanced immune response in avian species
US8877199B2 (en) 2009-05-15 2014-11-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services B cell surface reactive antibodies
LT2437753T (lt) 2009-06-05 2016-12-12 Infectious Disease Research Institute Sintetiniai gliukopiranozillipidų adjuvantai ir juos turinčios vakcinų kompozicijos
WO2010144611A2 (en) * 2009-06-10 2010-12-16 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
IN2012DN00352A (Direct) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
EP2442827B1 (en) 2009-06-16 2016-01-06 The Regents of the University of Michigan Nanoemulsion vaccines
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
US9089573B2 (en) 2009-07-22 2015-07-28 University Of Massachusetts Methods and compositions to reduce oxidative stress
AU2010277554B2 (en) 2009-07-30 2015-02-19 Antisense Pharma Gmbh Combination of a chemotherapeutic agent and an inhibitor of the TGF-beta system
EP2292260A1 (en) 2009-08-13 2011-03-09 Institut Pasteur Use of mycobacterium bovis BCG killed by extended freeze drying (EFD) for preventing or treating atherosclerosis
EP2287304A1 (en) 2009-08-17 2011-02-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel treatment of patients after stent implantation or balloon dilatation and novel drug eluting stents
AU2010284240B2 (en) 2009-08-18 2016-11-10 Array Biopharma, Inc. Substituted benzoazepines as Toll-like receptor modulators
US8524702B2 (en) 2009-08-18 2013-09-03 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
EP2477652B1 (en) 2009-09-16 2015-04-15 Vaxart, Inc. Immunization strategy to prevent h1n1 infection
WO2011041093A1 (en) 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
US20110104138A1 (en) 2009-11-03 2011-05-05 Institut Pasteur Use of the innate immunity gene oasl for preventing or treating infection with negative strand rna viruses
IN2012DN05145A (Direct) 2009-11-19 2015-10-23 Solis Biodyne
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
BR112012017473A2 (pt) 2010-01-13 2019-09-24 Institut National De La Sante Et De La Rech Medicale Inserm Epst pirido(1,2-a) pirimidinas, seu uso, bem como composição farmacêutica compreendendo tais compostos
ES2614266T3 (es) 2010-01-27 2017-05-30 Glaxosmithkline Biologicals S.A. Antígenos de tuberculosis modificados
US9556248B2 (en) 2010-03-19 2017-01-31 The Board Of Trustees Of The Leland Stanford Junior University Hepatocyte growth factor fragments that function as potent met receptor agonists and antagonists
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
US20110293585A1 (en) 2010-04-21 2011-12-01 Helix Therapeutics, Inc. Compositions and methods for treatment of lysosomal storage disorders
US20110262406A1 (en) 2010-04-21 2011-10-27 Yale University Compositions and methods for targeted inactivation of hiv cell surface receptors
EP3138915A1 (en) 2010-05-04 2017-03-08 The Brigham and Women's Hospital, Inc. Detection and treatment of fibrosis
WO2011138032A2 (en) 2010-05-05 2011-11-10 Artemev, Timur Universal influenza vaccines and methods for their generation
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
EP2595613B1 (en) 2010-07-22 2019-01-09 The U.S.A. as represented by the Secretary, Department of Health and Human Services Compounds for use in a method of preventing or treating viral infection
DK2601609T3 (en) 2010-08-02 2017-06-06 Population Bio Inc COMPOSITIONS AND METHODS FOR DISCOVERING MUTATIONS CAUSING GENETIC DISORDERS
AR083533A1 (es) 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
CN103492016A (zh) 2010-11-23 2014-01-01 普莱萨格生命科学公司 用于实体递送的治疗方法和组合物
CA2818992C (en) 2010-12-01 2021-05-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ror1 antibodies
UA118537C2 (uk) 2010-12-22 2019-02-11 Байєр Інтеллектуал Проперті Гмбх Композиція імуномодулятора для лікування респіратоного захворювання у великої рогатої худоби
EP3207930A1 (en) 2011-01-12 2017-08-23 VentiRx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
ES2620606T3 (es) 2011-01-12 2017-06-29 Ventirx Pharmaceuticals, Inc. Benzoazepinas sustituidas como moduladores de receptores tipo Toll
RU2615117C2 (ru) 2011-02-03 2017-04-04 Мирна Терапетикс, Инк. ДВУХЦЕПОЧЕЧНАЯ МОЛЕКУЛА РНК ДЛЯ ОБЕСПЕЧЕНИЯ КЛЕТКИ АКТИВНОСТЬЮ miR-34a
MX2013008944A (es) 2011-02-03 2014-01-08 Mirna Therapeutics Inc Mimeticos sinteticos de mir-124.
EP2683244B1 (en) 2011-03-08 2017-02-01 3-V Biosciences, Inc. Heterocyclic modulators of lipid synthesis
EP3345922A1 (en) 2011-03-09 2018-07-11 Cell Signaling Technology, Inc. Methods and reagents for creating monoclonal antibodies
CA2830503A1 (en) 2011-03-17 2012-09-20 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
CN103596586A (zh) 2011-04-08 2014-02-19 免疫设计公司 免疫原性组合物及使用所述组合物诱导体液和细胞免疫反应的方法
PL2694549T3 (pl) 2011-04-08 2019-01-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeryczne receptory antygenowe anty-wariant III receptora czynnika wzrostu naskórka i ich zastosowanie do leczenia raka
CN105148285B (zh) 2011-04-21 2019-02-12 塔夫茨大学信托人 用于活性试剂稳定化的方法和组合物
ES2583877T3 (es) 2011-06-01 2016-09-22 Janus Biotherapeutics, Inc. Moduladores novedosos del sistema inmunitario
JP6093759B2 (ja) 2011-06-01 2017-03-08 ジャナス バイオセラピューティクス，インク． 新規の免疫系調節剤
WO2012174064A1 (en) 2011-06-14 2012-12-20 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
CA2838981C (en) 2011-06-17 2020-09-08 University Of Tennessee Research Foundation Group a streptococcus multivalent vaccine
CN103608030A (zh) 2011-06-21 2014-02-26 昂科发克特公司 用于治疗和诊断癌症的组合物和方法
EP2734843A2 (en) 2011-07-18 2014-05-28 President and Fellows of Harvard College Engineered microbe-targeting molecules and uses thereof
WO2013013061A1 (en) 2011-07-19 2013-01-24 University Of Vermont And State Agricultural College Methods and compounds for treating cancer
US8324264B1 (en) 2011-07-22 2012-12-04 Sequoia Sciences, Inc. Inhibitors of bacterial biofilms and related methods
WO2013020044A1 (en) 2011-08-03 2013-02-07 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center Treatment of fibrosis using microrna-19b
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
JP2014528449A (ja) 2011-10-04 2014-10-27 ジャナス バイオセラピューティクス，インク． 新規なイミダゾールキノリン系免疫系調節剤
WO2013054200A2 (en) 2011-10-10 2013-04-18 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
CA2852244C (en) 2011-10-17 2023-10-17 Minerva Biotechnologies Corporation Media for stem cell proliferation and induction
CN109485730A (zh) 2011-10-20 2019-03-19 美国卫生和人力服务部 抗cd22嵌合抗原受体
JP2014534864A (ja) 2011-10-28 2014-12-25 プレサージュ バイオサイエンシズ，インコーポレイテッド 薬物デリバリー方法
DK2773779T3 (da) 2011-11-04 2020-11-23 Population Bio Inc Fremgangsmåder og sammensætninger til diagnosticering, prognose og forebyggelse af neurologiske tilstande
BR112014011417B1 (pt) 2011-11-11 2021-10-13 Fred Hutchinson Cancer Research Center Polipeptídeo isolado capaz de elicitar uma resposta de célula t antígeno-específica para ciclina a1 humana, composição imunogênica compreendendo o referido polipeptídeo, bem como método para preparar células apresentadoras de antígeno, antígeno-pulsadas,e uso destas para superexpressão de ccna1
CA2862807A1 (en) 2011-11-30 2013-06-06 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US9173884B2 (en) 2011-11-30 2015-11-03 Trustees Of Boston College Inhibitors of phosphodiesterase 11 (PDE11)
WO2013119856A1 (en) 2012-02-07 2013-08-15 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
DK2812452T3 (da) 2012-02-09 2020-06-29 Population Bio Inc Fremgangsmåder og sammensætninger til screening og behandling af udviklingsforstyrrelser
CN103251941A (zh) * 2012-02-16 2013-08-21 海南大学 动物病毒性疫苗脉冲释放系统、其制备方法及用途
EP2836224A4 (en) 2012-02-29 2015-12-16 Ethicon Endo Surgery Inc COMPOSITIONS OF BIOZOOSE AND RELATED METHODS
WO2013134577A2 (en) 2012-03-08 2013-09-12 Detectogen, Inc. Leishmaniasis antigen detection assays and vaccines
CA3116051C (en) 2012-03-23 2023-09-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
ES2719495T5 (en) 2012-05-07 2025-09-10 Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
HRP20181102T1 (hr) 2012-05-16 2018-09-07 Immune Design Corp Cjepiva za hsv-2
AU2013290266B2 (en) 2012-07-11 2018-05-10 University Of Vermont And State Agricultural College Method and composition for metabolic regulation
JP6246121B2 (ja) 2012-07-13 2017-12-13 株式会社新日本科学 キラル核酸アジュバント
JP6302909B2 (ja) 2012-08-18 2018-03-28 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ シアリダーゼの同定および画像化のための細胞透過性プローブ
US9119858B2 (en) 2012-08-21 2015-09-01 Genesys Research Institute, Inc. Compositions and methods for treating or preventing anthracycline induced cardiotoxicity
DK2895621T3 (da) 2012-09-14 2020-11-30 Population Bio Inc Fremgangsmåder og sammensætning til diagnosticering, prognose og behandling af neurologiske tilstande
CA2922005A1 (en) 2012-09-27 2014-04-03 Population Diagnostics, Inc. Methods and compositions for screening and treating developmental disorders
US9228184B2 (en) 2012-09-29 2016-01-05 Dynavax Technologies Corporation Human toll-like receptor inhibitors and methods of use thereof
EP2904119B1 (en) 2012-10-02 2020-06-17 The General Hospital Corporation d/b/a Massachusetts General Hospital Methods relating to dna-sensing pathway related conditions
EP2912061B1 (en) 2012-10-24 2019-02-06 The United States of America, as represented by The Secretary, Department of Health and Human Services M971 chimeric antigen receptors
WO2014074805A1 (en) 2012-11-08 2014-05-15 Whitehead Institute For Biomedical Research Selective targeting of cancer stem cells
US9872851B2 (en) 2012-12-12 2018-01-23 The Charlotte-Mecklenburg Hospital Authority Methods of treating portal hypertension
WO2014093711A1 (en) 2012-12-12 2014-06-19 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System Methods of treating hepatic fibrosis and associated diseases by regulating rev-erb activity
WO2014127825A1 (en) 2013-02-21 2014-08-28 Boehringer Ingelheim Vetmedica Gmbh H5 proteins of h5n1 influenza virus for use as a medicament
JP6457999B2 (ja) 2013-03-14 2019-01-23 ザ チルドレンズ メディカル センター コーポレーション 処置に関してがんの対象を識別するためのｃｄ３６の使用
US9498612B2 (en) 2013-03-14 2016-11-22 Hallux, Inc. Method of treating infections, diseases or disorders of nail unit
US11376329B2 (en) 2013-03-15 2022-07-05 Trustees Of Tufts College Low molecular weight silk compositions and stabilizing silk compositions
US20160046679A1 (en) 2013-03-15 2016-02-18 Trustees Of Tufts College Low molecular weight silk compositions and stabilizing silk compositions
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
JP2016522165A (ja) 2013-04-04 2016-07-28 イエオ−イスティトゥート・エウロペオ・ディ・オンコロジア・エッセ・エッレ・エッレ 胸腺間質性リンパ球新生因子フラグメント及びその使用
HK1214510A1 (zh) 2013-04-18 2016-07-29 Immune Design Corp. 用於癌症治疗的gla单一疗法
WO2014182635A1 (en) 2013-05-08 2014-11-13 Baldwin Megan E Biomarkers for age-related macular degeneration (amd)
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
AU2014301958B2 (en) 2013-06-25 2017-11-16 The Walter And Eliza Hall Institute Of Medical Research Method of treating intracellular infection
EP3013365B1 (en) 2013-06-26 2019-06-05 Academia Sinica Rm2 antigens and use thereof
US10231993B2 (en) 2013-06-27 2019-03-19 University Of Washington Through Its Center For Commercialization Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders
EP3013347B1 (en) 2013-06-27 2019-12-11 Academia Sinica Glycan conjugates and use thereof
WO2015006543A1 (en) 2013-07-10 2015-01-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for predicting and detecting tumor metastasis in kidney cancer
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
GB2535034A (en) 2013-07-21 2016-08-10 Whole Biome Inc Methods and systems for microbiome characterization, monitoring and treatment
CN105682666B (zh) 2013-09-06 2021-06-01 中央研究院 使用醣脂激活人类iNKT细胞
CN105828833A (zh) 2013-10-21 2016-08-03 萨克生物研究学院 突变的成纤维细胞生长因子（fgf）1及使用方法
CA2928700C (en) 2013-11-01 2019-01-15 University Of Oslo Albumin variants and uses thereof
DK3069138T3 (en) 2013-11-15 2019-04-08 Univ Oslo Hf CTL PEPTID EPITOPES AND ANTIGEN-SPECIFIC T-CELLS, METHODS OF RECOGNITION THEREOF, AND APPLICATIONS THEREOF
CN105899531B (zh) 2013-12-06 2022-02-25 美国卫生和人力服务部 胸腺基质淋巴细胞生成素受体特异性的嵌合抗原受体及其使用方法
WO2015095604A2 (en) 2013-12-18 2015-06-25 President And Fellows Of Harvard College Methods and assays relating to circulating tumor cells
CN106061963B (zh) 2013-12-20 2019-10-22 3-V生物科学股份有限公司 脂质合成的杂环调节剂和其组合
JP6522007B2 (ja) 2014-01-07 2019-05-29 ３−ブイ・バイオサイエンシーズ・インコーポレイテッド３−Ｖ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 癌及びウイルス感染症に対する使用のための脂質合成の複素環式モジュレータ
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
JPWO2015108047A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
CA2937123A1 (en) 2014-01-16 2015-07-23 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
MX2016009464A (es) 2014-01-21 2017-01-16 Immune Design Corp Composiciones para el uso en el tratamiento de afecciones alergicas.
KR102396817B1 (ko) 2014-02-20 2022-05-11 박사르트, 인크. 소장 전달을 위한 제형들
KR20160122849A (ko) 2014-02-28 2016-10-24 바이엘 애니멀 헬스 게엠베하 면역자극성 플라스미드
WO2015138852A1 (en) 2014-03-14 2015-09-17 University Of Washington Genomic insulator elements and uses thereof
WO2015148801A1 (en) 2014-03-26 2015-10-01 Children's Medical Center Corporation Cyclic prosaposin peptides and uses thereof
JP6562942B2 (ja) 2014-03-27 2019-08-28 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 反応性標識化合物およびその使用
CN120514834A (zh) 2014-03-28 2025-08-22 华盛顿大学商业中心 乳腺癌和卵巢癌疫苗
US10398672B2 (en) 2014-04-29 2019-09-03 Whitehead Institute For Biomedical Research Methods and compositions for targeting cancer stem cells
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
EP3721875B1 (en) 2014-05-09 2023-11-08 Yale University Particles coated with hyperbranched polyglycerol and methods for their preparation
CN106573971A (zh) 2014-05-27 2017-04-19 中央研究院 抗cd20醣抗体及其用途
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR20170005142A (ko) 2014-05-27 2017-01-11 아카데미아 시니카 증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법
JP7062361B2 (ja) 2014-05-27 2022-05-06 アカデミア シニカ 抗ｈｅｒ２糖操作抗体群およびその使用
TWI732738B (zh) 2014-05-28 2021-07-11 中央研究院 抗TNF-α醣抗體及其用途
EP3169699A4 (en) 2014-07-18 2018-06-20 The University of Washington Cancer vaccine compositions and methods of use thereof
JP2017525711A (ja) 2014-08-22 2017-09-07 ジャナス バイオセラピューティクス，インク． 新規なｎ２，ｎ４，ｎ７，６−四置換プテリジン−２，４，７−トリアミンおよび２，４，６，７−四置換プテリジン化合物ならびにその合成方法および使用
WO2016036403A1 (en) 2014-09-05 2016-03-10 Population Diagnostics Inc. Methods and compositions for inhibiting and treating neurological conditions
EP3191500A4 (en) 2014-09-08 2018-04-11 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
EP3193933B1 (en) 2014-09-17 2021-04-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Anti-cd276 antibodies (b7h3)
WO2016054240A1 (en) 2014-09-30 2016-04-07 Sean Dalziel Fixed dose combinations for the treatment of viral diseases
EP4112076A1 (en) 2014-10-10 2023-01-04 The Regents of The University of Michigan Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
EP3207150B1 (en) 2014-10-14 2021-04-28 Research Development Foundation Methods for generating engineered enzymes
SG11201703395PA (en) 2014-10-31 2017-05-30 Whole Biome Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
EP3229586B1 (en) 2014-12-10 2025-07-30 Regents of the University of Minnesota Genetically modified cells, tissues, and organs for treating disease
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2016118191A1 (en) 2015-01-24 2016-07-28 Academia Sinica Novel glycan conjugates and methods of use thereof
US11746159B2 (en) 2015-02-10 2023-09-05 Minerva Biotechnologies Corporation Humanized anti-MUC1* antibodies
AU2016220024B2 (en) 2015-02-18 2020-10-15 University Of Vermont And State Agricultural College MCJ agonists and uses therefor
US10647964B2 (en) 2015-03-05 2020-05-12 Northwestern University Non-neuroinvasive viruses and uses thereof
KR20170129151A (ko) 2015-03-19 2017-11-24 3-브이 바이오사이언시스, 인코포레이티드 지질 합성의 복소환식 조절제
EP3270937A4 (en) 2015-03-26 2018-09-12 The Trustees Of Dartmouth College Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
CA3019311A1 (en) 2015-04-15 2016-10-20 University Of Massachusetts Compositions and methods for xi chromosome reactivation
US20180117155A1 (en) 2015-04-25 2018-05-03 The General Hospital Corporation Anti-fugetactic agent and anti-cancer agent combination therapy and compositions for the treatment of cancer
KR20180033499A (ko) 2015-06-05 2018-04-03 아이바이오, 인크. 섬유증을 치료하는데 사용하기 위한 엔도스타틴 단편 및 변이체
US11433146B2 (en) 2015-06-12 2022-09-06 Vaxart, Inc. Formulations for small intestinal delivery of RSV and norovirus antigens
US10633427B2 (en) 2015-06-26 2020-04-28 Prindex S.R.L. Diagnosis and therapy of multiple sclerosis
CA2991911A1 (en) 2015-07-10 2017-01-19 University Of Vermont And State Agricultural College Methods and compositions to treat drug-induced diseases and conditions
US11439703B2 (en) 2015-07-31 2022-09-13 ELANCO US, Inc. Enhanced immune response in porcine species
EP3763378A1 (en) 2015-08-06 2021-01-13 President and Fellows of Harvard College Improved microbe-binding molecules and uses thereof
US10457941B2 (en) 2015-08-20 2019-10-29 ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS-CIC bioGUNE Methods and compositions to treat liver diseases and conditions
CA2998745A1 (en) 2015-09-17 2017-03-23 University Of Massachusetts Compositions and methods for modulating fmr1 expression
EP3349797A4 (en) 2015-09-18 2019-06-12 The General Hospital Corporation Dba Massachusetts General Hospital LOCALIZED RELEASE OF ANTIFUGETACTIC AGENT FOR THE TREATMENT OF CANCER
UA126278C2 (uk) 2015-09-21 2022-09-14 Аптево Рісьорч Енд Девелопмент Ллс Поліпептиди, які зв'язують cd3
WO2017096304A1 (en) 2015-12-04 2017-06-08 Board Of Regents, The University Of Texas System Slc45a2 peptides for immunotherapy
KR20180101554A (ko) 2016-01-20 2018-09-12 더 스크립스 리서치 인스티튜트 Ｒｏｒ１ 항체 조성물 및 관련 방법
KR20180099887A (ko) 2016-01-20 2018-09-05 더 스크립스 리서치 인스티튜트 Ｒｏｒ2 항체 조성물 및 관련 방법
CA3014795A1 (en) 2016-02-16 2017-08-24 Yale University Compositions and methods for treatment of cystic fibrosis
US11136597B2 (en) 2016-02-16 2021-10-05 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
WO2017156192A1 (en) 2016-03-08 2017-09-14 Academia Sinica Methods for modular synthesis of n-glycans and arrays thereof
WO2017173334A1 (en) 2016-04-01 2017-10-05 Checkmate Pharmaceuticals, Inc. Fc receptor-mediated drug delivery
CN116333140A (zh) 2016-04-08 2023-06-27 埃缇健康公司D/B/A泽尔拜尔 网蛋白-1结合抗体及其用途
JP2019527065A (ja) 2016-05-04 2019-09-26 アビリタ バイオ，インク． 複数膜貫通型タンパク質を調製する方法とプラットフォーム
EP3454891A4 (en) 2016-05-10 2019-12-25 The Regents of The University of Michigan EMULSION ADJUVANS FOR INTRAMUSCULAR, INTRADERMAL AND SUBCUTANEOUS ADMINISTRATION
EP3458028A1 (en) 2016-05-16 2019-03-27 Infectious Disease Research Institute Pegylated liposomes and methods of use
EP3458475B1 (en) 2016-05-16 2022-07-27 Access to Advanced Health Institute Formulation containing tlr agonist and methods of use
EP3464366A1 (en) 2016-05-27 2019-04-10 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Flt3-specific chimeric antigen receptors and methods using same
WO2017207623A1 (en) 2016-05-31 2017-12-07 Université de Lausanne Mirna as biomarkers and regulators of cancer stem cells
RU2753874C2 (ru) 2016-06-01 2021-08-24 Инфекшес Дизис Рисёрч Инститьют Наноалюмочастицы, содержащие агент, регулирующий размер
US20190322643A1 (en) 2016-06-29 2019-10-24 Georgia State University Research Foundation, Inc. Histone deacetylase and histone methyltransferase inhibitors and methods of making and use of the same
WO2018005759A1 (en) 2016-07-01 2018-01-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitor of heme degradation for use to improve antibiotic treatment of mycobacterium tuberculosis infection
SG11201900710YA (en) 2016-07-26 2019-02-27 Bayer Animal Health Gmbh Increased fertility in bovine species
EP3500594A4 (en) 2016-08-22 2020-03-11 Cho Pharma Inc. ANTIBODIES, BINDING FRAGMENTS AND METHOD FOR USE
JP2019534249A (ja) 2016-09-09 2019-11-28 ザ ジェネラル ホスピタル コーポレイション 癌の治療のための抗化学忌避剤とのｈｓｐ融合タンパク質
WO2018049120A1 (en) 2016-09-09 2018-03-15 The General Hospital Corporation Ex vivo antigen-presenting cells or activated cd-positive t cells for treatment of cancer
WO2018049124A1 (en) 2016-09-09 2018-03-15 The General Hospital Corporation Hsp fusion protein with anti-chemorepellant agent for treatment of infectious disease
WO2018063472A1 (en) 2016-09-27 2018-04-05 Reyoung Corporation Compositions for treating parasitic diseases and methods thereof
US11725232B2 (en) 2016-10-31 2023-08-15 The Hong Kong University Of Science And Technology Compositions, methods and kits for detection of genetic variants for alzheimer's disease
EP3535588A4 (en) 2016-11-07 2020-09-16 University of Massachusetts THERAPEUTIC TARGET MOLECULES FOR FACIO-CAPULOHUMERAL MUSCLE DYSTROPHY
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
US10240205B2 (en) 2017-02-03 2019-03-26 Population Bio, Inc. Methods for assessing risk of developing a viral disease using a genetic test
EP3576726A1 (en) 2017-02-06 2019-12-11 Massachusetts Institute Of Technology Methods and products related to glutaminase inhibitors
US11260132B2 (en) 2017-03-16 2022-03-01 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
EP3600395A4 (en) 2017-03-23 2021-05-05 The General Hospital Corporation BLOCKING OF CXCR4 / CXCR7 AND TREATMENT OF HUMAN PAPILLOMAVIRUS-ASSOCIATED DISEASE
US11920125B2 (en) 2017-03-27 2024-03-05 Tenfold Technologies, LLC Methods and agricultural compositions for preventing or controlling plant diseases
EP3600554A4 (en) 2017-03-27 2021-01-13 Tenfold Technologies, LLC ANTIPATHOGENIC COMPOSITION AND METHODS FOR USING THE SAME
WO2018187493A1 (en) 2017-04-04 2018-10-11 Yale University Compositions and methods for in utero delivery
US11225512B2 (en) 2017-04-27 2022-01-18 University Of New Hampshire Compositions and methods for ceramide-elevating therapeutic strategies
WO2018213612A1 (en) 2017-05-18 2018-11-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin polypeptides and proteins
AU2018283973B2 (en) 2017-06-11 2025-04-24 Molecular Express, Inc. Methods and compositions for substance use disorder vaccine formulations and uses thereof
WO2018232257A1 (en) 2017-06-15 2018-12-20 Infectious Disease Research Institute Nanostructured lipid carriers and stable emulsions and uses thereof
US11642362B2 (en) 2017-07-06 2023-05-09 National University Of Singapore Methods of inhibiting cell proliferation and METTL8 activity
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
CN111629716A (zh) 2017-07-14 2020-09-04 马萨诸塞大学 治疗炎症的方法和组合物
EP3655437A1 (en) 2017-07-20 2020-05-27 NBE-Therapeutics AG Human antibodies binding to ror2
SG11202000846WA (en) 2017-08-07 2020-02-27 Nbe Therapeutics Ag Anthracycline-based antibody drug conjugates having high in vivo tolerability
AU2018326705A1 (en) 2017-08-30 2020-03-05 Pendulum Therapeutics, Inc. Methods and compositions for treatment of microbiome-associated disorders
US12005112B2 (en) 2017-09-07 2024-06-11 University Of Oslo Vaccine molecules
US12268736B2 (en) 2017-09-07 2025-04-08 University Of Oslo Vaccine molecules
CN111433222B (zh) 2017-10-12 2025-01-28 得克萨斯大学体系董事会 用于免疫疗法的t细胞受体
WO2019108656A1 (en) 2017-11-28 2019-06-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Microbicidal composition
WO2019154884A1 (en) 2018-02-07 2019-08-15 Ecole Polytechnique Federale De Lausanne (Epfl) Method for determining cancer invasiveness and patient prognosis
CN112119092A (zh) 2018-02-12 2020-12-22 无糖尿病公司 改进的拮抗性抗人cd40单克隆抗体
EP3752194A4 (en) 2018-02-13 2022-03-16 Checkmate Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR TUMOR IMMUNOTHERAPY
MX2020010410A (es) 2018-04-09 2021-01-15 Checkmate Pharmaceuticals Empaquetado de oligonucleotidos en particulas similares a virus.
WO2019204154A1 (en) 2018-04-18 2019-10-24 Reyoung Corporation Compositions and methods for treating liver cancer
PT3773537T (pt) 2018-04-19 2022-04-19 Baylor College Medicine Inibidores de stat3
WO2019217164A1 (en) 2018-05-09 2019-11-14 Reyoung Corporation Compositions and methods for treating cancer and other diseases
BR112020024292A2 (pt) 2018-06-06 2021-03-02 Massachusetts Institute Of Technology rna circular para translação em células eucarióticas
KR20240014102A (ko) 2018-06-29 2024-01-31 우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 레버 유전성 시신경병증의 치료를 위한 조성물 및 방법
WO2020001657A1 (en) 2018-06-29 2020-01-02 Wuhan Neurophth Biological Technology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
CN113164526A (zh) 2018-07-19 2021-07-23 潘德勒姆治疗公司 用于微生物植入的方法和组合物
EP4177356B1 (en) 2018-08-08 2024-05-08 PML Screening, LLC Methods for assessing risk of developing a viral disease using a genetic test
EP3840785A4 (en) 2018-08-20 2022-07-13 Wuhan Neurophth Biotechnology Limited Company COMPOSITIONS AND METHODS FOR THE TREATMENT OF LEBERIAN OPTIC ATROPHY
ES2990218T3 (es) 2018-08-22 2024-11-29 Bacainn Biotherapeutics Ltd Composiciones de ciclosporina y métodos de uso
CN112930399A (zh) 2018-08-31 2021-06-08 耶鲁大学 用于增强基于供体寡核苷酸的基因编辑的组合物和方法
MX2021002266A (es) 2018-08-31 2021-05-27 Univ Yale Composiciones y metodos para aumentar la edicion de genes basados en nucleasa y triplex.
WO2020051766A1 (zh) 2018-09-11 2020-03-19 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
US20210346462A1 (en) 2018-10-04 2021-11-11 Rutgers, The State University Of New Jersey Methods of reducing type 2 cytokine-mediated inflammation using neuromedin peptides
WO2020081737A1 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Compositions and methods for inducing intestinal stem cell regeneration
JP7658579B2 (ja) 2018-10-19 2025-04-08 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 操作された長鎖散在反復エレメント（ｌｉｎｅ）トランスポゾンおよびそれらの使用方法
WO2020102454A1 (en) 2018-11-13 2020-05-22 Regents Of The University Of Minnesota Cd40 targeted peptides and uses thereof
CA3119728A1 (en) 2018-11-21 2020-05-28 Tremeau Pharmaceuticals, Inc. Purified forms of rofecoxib, methods of manufacture and use
EP3677693A1 (en) 2019-01-03 2020-07-08 Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO Transpochimeric gene trancripts (tcgts) as cancer biomarkers
US12077592B2 (en) 2019-01-18 2024-09-03 Janssen Biotech, Inc. GPRC5D chimeric antigen receptors and cells expressing the same
BR112021014657A2 (pt) 2019-01-30 2021-09-21 Janssen Pharmaceutica N.V. Métodos para tratar câncer de próstata com base em subtipos moleculares
WO2020186187A1 (en) 2019-03-13 2020-09-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating bladder and urethra dysfunction and disease
CN114206389A (zh) 2019-03-21 2022-03-18 有丝分裂疗法有限责任公司 用于靶向递送治疗剂的多价配体簇
US20220160771A1 (en) 2019-04-10 2022-05-26 Iulia Diaconu Flt3-specific chimeric antigen receptors and methods of using the same
AU2020280105A1 (en) 2019-05-22 2022-01-20 Massachusetts Institute Of Technology Circular RNA compositions and methods
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
US20220372474A1 (en) 2019-06-21 2022-11-24 Yale University Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
US20220243211A1 (en) 2019-06-21 2022-08-04 Yale University Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
WO2021011529A1 (en) 2019-07-15 2021-01-21 Rovaxa Opioid growth factor receptor (ogfr) antagonists, in particular naloxone and/or naltrexone for treating cancer
CA3147735A1 (en) 2019-07-26 2021-02-04 Janssen Biotech, Inc. Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
CN114174346B (zh) 2019-07-26 2025-08-01 詹森生物科技公司 抗hk2嵌合抗原受体(car)
WO2021022161A1 (en) 2019-07-31 2021-02-04 Yale University Compositions and methods for treating sickle cell disease
EP4013788A1 (en) 2019-08-12 2022-06-22 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
CN112390894A (zh) 2019-08-12 2021-02-23 广东东阳光药业有限公司 嵌合抗原受体及其应用
US20210047423A1 (en) 2019-08-16 2021-02-18 Janssen Biotech, Inc. Therapeutic immune cells with improved function and methods for making the same
CN115151275A (zh) 2019-08-30 2022-10-04 耶鲁大学 用于向细胞递送核酸的组合物和方法
WO2021071806A1 (en) 2019-10-07 2021-04-15 D. E. Shaw Research, Llc Arylmethylene heterocyclic compounds as kv1.3 potassium shaker channel blockers
TW202128775A (zh) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
KR20220114560A (ko) 2019-11-18 2022-08-17 얀센 바이오테크 인코포레이티드 항-cd79 키메라 항원 수용체, car-t 세포 및 이의 용도
CN113025633B (zh) 2019-12-09 2024-08-27 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
EP3868396A1 (en) 2020-02-20 2021-08-25 Enthera S.R.L. Inhibitors and uses thereof
US20230092615A1 (en) 2020-02-21 2023-03-23 Mitotherapeutix Llc Compositions and methods for inhibiting expressing of methylation-controlled j-protein (mcj)
CN115768482A (zh) 2020-03-13 2023-03-07 詹森生物科技公司 结合siglec-3/cd33的材料和方法
US20230181672A1 (en) 2020-05-07 2023-06-15 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms
EP4146667A4 (en) 2020-05-08 2024-06-19 Georgiamune Inc. AKT3 MODULATORS
JP2023527309A (ja) 2020-05-19 2023-06-28 オルナ セラピューティクス インコーポレイテッド 環状ｒｎａ組成物及び方法
TW202208418A (zh) 2020-05-21 2022-03-01 美國德州系統大學評議委員會 具有vgll1特異性之t細胞受體及其用途
WO2021245285A1 (en) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
CA3190174A1 (en) 2020-08-03 2022-02-10 Janssen Biotech, Inc. Materials and methods for multidirectional biotransportation in virotherapeutics
KR20230079367A (ko) 2020-08-31 2023-06-07 예일 유니버시티 핵산을 세포에 전달하기 위한 조성물 및 방법
CA3174411A1 (en) 2020-09-04 2022-03-10 Ryan M. Kramer Co-lyophilized rna and nanostructured lipid carrier
US20230310569A1 (en) 2020-09-04 2023-10-05 Access To Advanced Health Institute Genetically-adjuvanted rna vaccines
WO2022051023A1 (en) 2020-09-04 2022-03-10 Infectious Disease Research Institute Live-attenuated rna hybrid vaccine technology
CN116615256A (zh) 2020-10-16 2023-08-18 乔治亚大学研究基金会 糖缀合物
EP4059498A1 (en) 2021-03-16 2022-09-21 Centre Hospitalier Universitaire Vaudois (CHUV) Methods and compositions for treating conditions associated with hypermineralization
US12180278B2 (en) 2021-03-24 2024-12-31 Janssen Biotech, Inc. Antibody targeting CD22 and CD79B
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
WO2022237974A1 (en) 2021-05-12 2022-11-17 Ecole Polytechnique Federale De Lausanne (Epfl) Krab-containing zinc finger protein and cancer
PH12023553237A1 (en) 2021-05-28 2024-04-29 De Shaw Res Llc Spiroindolinone compounds as kv1.3 potassium shaker channel blockers
CN115404240A (zh) 2021-05-28 2022-11-29 上海环码生物医药有限公司 制备环形rna的构建体、方法及其用途
EP4352226A1 (en) 2021-06-07 2024-04-17 Yale University Peptide nucleic acids for spatiotemporal control of crispr-cas binding
WO2022271955A1 (en) 2021-06-23 2022-12-29 Musc Foundation For Research Development Novel targeted shrna nanoparticles for cancer therapy
WO2023280157A1 (zh) 2021-07-05 2023-01-12 武汉纽福斯生物科技有限公司 一种抗vegf抗体体内表达系统的构建和应用
EP4382601A4 (en) 2021-08-06 2025-07-30 Wuhan Neurophth Biotechnology Ltd Company COMPOSITION AND METHOD OF TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY CAUSED BY THE ND4 MUTATION
US12129302B2 (en) 2021-08-25 2024-10-29 Ibio, Inc. Anti-CD-25 antibody
WO2023046322A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceutica Nv Proteins comprising cd20 binding domains, and uses thereof
US20250243277A1 (en) 2021-10-07 2025-07-31 Avacta Life Sciences Limited Pd-l1 binding affimers
WO2023057946A1 (en) 2021-10-07 2023-04-13 Avacta Life Sciences Limited Serum half-life extended pd-l1 binding polypeptides
CA3236235A1 (en) 2021-11-08 2023-05-11 Orna Therapeutics, Inc. Lipid nanoparticle compositions for delivering circular polynucleotides
JP2024543496A (ja) 2021-11-16 2024-11-21 シャンハイ アルゴ バイオファーマシューティカル カンパニー，リミテッド アンギオテンシノゲン（ａｇｔ）タンパク質の発現を阻害する組成物及び方法
TW202329987A (zh) 2021-11-29 2023-08-01 大陸商上海舶望製藥有限公司 用於抑制乙型肝炎病毒（hbv）蛋白表達的組合物和方法
TW202345865A (zh) 2022-01-24 2023-12-01 大陸商上海舶望製藥有限公司 抑制LPA(Apo(a))蛋白表達的組合物和方法
CN119213021A (zh) 2022-02-10 2024-12-27 艾菲赛尔治疗株式会社 与CD40L特异性结合的Stefin A蛋白变体及其用途
US20250289903A1 (en) 2022-04-29 2025-09-18 Purinnomia Biotech, Inc. Methods and compositions for treating eosinophil driven diseases and disorders
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins
CN120092091A (zh) 2022-05-30 2025-06-03 上海环码生物医药有限公司 合成的环状rna组合物及其使用方法
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
JP2025530217A (ja) 2022-09-09 2025-09-11 イェール ユニバーシティー タンパク質分解標的化抗体およびその使用の方法
AU2023336224A1 (en) 2022-09-09 2025-03-27 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin
WO2024081736A2 (en) 2022-10-11 2024-04-18 Yale University Compositions and methods of using cell-penetrating antibodies
WO2024094526A1 (en) 2022-11-02 2024-05-10 Ecole Polytechnique Federale De Lausanne (Epfl) 6-diazo-5-oxo-l-norleucine prodrugs
WO2024102762A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
TW202425959A (zh) 2022-11-08 2024-07-01 美商歐納醫療公司 遞送多核苷酸的脂質及奈米顆粒組合物
WO2024114776A1 (zh) 2022-12-02 2024-06-06 上海舶望制药有限公司 双环脱碱基核酸类似物以及由它们制备的寡聚化合物
EP4634390A2 (en) 2022-12-15 2025-10-22 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2024205657A2 (en) 2023-03-29 2024-10-03 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
EP4678646A1 (en) 2023-04-06 2026-01-14 Shanghai Argo Biopharmaceutical Co., Ltd. Nucleoside analog for 5'-phosphonate modification and oligonucleotide prepared therefrom
AU2024269222A1 (en) 2023-05-05 2025-10-09 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2024263649A1 (en) 2023-06-19 2024-12-26 Yale University Methods and compositions for enrichment and sequencing of expansion-specific rna transcripts
WO2025007148A1 (en) 2023-06-30 2025-01-02 Orna Therapeutics, Inc. Polymer lipid nanoparticle compositions for delivering circular polynucleotides
WO2025021993A1 (en) 2023-07-27 2025-01-30 Omnilinx Therapeutics Ag Endocytic and scavenger receptor-targeting chimeric proteins and uses thereof
TW202521512A (zh) 2023-07-31 2025-06-01 美商美國禮來大藥廠 Kv1.3鉀shaker通道阻斷劑之固體形式及其使用方法
US11957676B1 (en) 2023-08-07 2024-04-16 Zetagen Therapeutics, Inc. Controlled release formulation and minimally invasive method of administration to locally treat cancer
WO2025049690A1 (en) 2023-08-29 2025-03-06 Orna Therapeutics, Inc. Circular polyethylene glycol lipids
WO2025052303A1 (en) 2023-09-08 2025-03-13 Beigene Switzerland Gmbh Circular rna and preparation methods thereof
EP4537907A1 (en) 2023-10-10 2025-04-16 Enthera S.r.l. Cd248 inhibitors and uses thereof
WO2025097000A1 (en) 2023-11-01 2025-05-08 Yale University Antibody-based methods for treating polycystic kidney disease
WO2025117969A1 (en) 2023-12-01 2025-06-05 Orna Therapeutics, Inc. Process for manufacturing lipid nanoparticles
WO2025247961A1 (en) 2024-05-31 2025-12-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Lpa-lpar signaling as a therapeutic target or diagnostic tool for brain diseases
WO2025257173A1 (en) 2024-06-13 2025-12-18 Ideogen A.G. Combination therapy for treating cancer such as lymphoma
WO2025257176A1 (en) 2024-06-13 2025-12-18 Ideogen A.G. Combination therapy for treating cancer such as lymphoma
WO2025257171A1 (en) 2024-06-13 2025-12-18 Ideogen A.G. Combination therapy for treating cancer such as lymphoma

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166800A (en) * 1977-08-25 1979-09-04 Sandoz, Inc. Processes for preparation of microspheres
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4526938A (en) * 1982-04-22 1985-07-02 Imperial Chemical Industries Plc Continuous release formulations
US4585651A (en) * 1978-10-17 1986-04-29 Stolle Research & Development Corporation Active/passive immunization of the internal female reproductive organs
US4681752A (en) * 1981-06-04 1987-07-21 Laboratorio Farmaceutico Lafarma S.A.S. Capsules containing the active principle of an allergen, and process for their preparation

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2738303A (en) * 1952-07-18 1956-03-13 Smith Kline French Lab Sympathomimetic preparation
US3823228A (en) * 1971-09-29 1974-07-09 Univ Illinois Tge virus vaccine
CH594444A5 (Direct) * 1972-12-04 1978-01-13 Gerd Birrenbach
FR2287216A1 (fr) * 1974-10-09 1976-05-07 Narcisse Guy Nouvelle forme galenique d'administration de medicaments et medicaments prepares sous cette nouvelle forme
DK143689C (da) * 1975-03-20 1982-03-15 J Kreuter Fremgangsmaade til fremstilling af en adsorberet vaccine
DE2702952A1 (de) * 1976-02-04 1977-08-11 Medichemie Ag Kreislaufregulierendes, oral anzuwendendes arzneimittel
US4291016A (en) * 1976-07-27 1981-09-22 Sandoz Ltd. Enteric coated mixture of 4-(2-hydroxy-3-isopropylamino-propoxy) indole and sodium lauryl sulphate
US4123519A (en) * 1976-08-17 1978-10-31 Philips Roxane, Inc. Injectable contraceptive vaccine and method
FR2408345A1 (fr) * 1976-11-30 1979-06-08 Besins Jean Louis Nouvelle composition a action anti-conceptionnelle
JPS58318B2 (ja) * 1977-07-11 1983-01-06 住友化学工業株式会社 制癌性物質の製造方法
US4152415A (en) * 1978-08-18 1979-05-01 Iowa State University Research Foundation, Inc. Method of increasing the effectiveness of oral vaccination for swine dysentery
US4203968A (en) * 1978-08-18 1980-05-20 Iowa State University Research Foundation, Inc. Combination vaccine for swine dysentery and method of use
US4152413A (en) * 1978-08-18 1979-05-01 Chromalloy American Corporation Oral vaccine for swine dysentery and method of use
US4152414A (en) * 1978-08-18 1979-05-01 Iowa State University Research Foundation, Inc. Combination vaccine for swine dysentery and method of use
US4732763A (en) * 1978-10-17 1988-03-22 Stolle Research And Development Corporation Active/passive immunization of the internal female reproductive organs
US4309406A (en) * 1979-07-10 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4298002A (en) * 1979-09-10 1981-11-03 National Patent Development Corporation Porous hydrophilic materials, chambers therefrom, and devices comprising such chambers and biologically active tissue and methods of preparation
GB2058562B (en) * 1979-09-14 1983-11-30 Beecham Group Ltd Pharmaceutical compositions containing paracetamol and ascorbic acid
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
US4439199A (en) * 1980-02-19 1984-03-27 Alza Corporation Method for administering immunopotentiator
US4384975A (en) * 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4455142A (en) * 1980-07-07 1984-06-19 Alza Corporation Method of coadministering an antigen and an immunopotentiator
JPS5719662A (en) * 1980-07-09 1982-02-01 Fuji Photo Film Co Ltd Preparation of microcapsule reagent for immune reaction
JPS5719660A (en) * 1980-07-09 1982-02-01 Fuji Photo Film Co Ltd Microcapsule for immune reaction
US4326524A (en) * 1980-09-30 1982-04-27 Minnesota Mining And Manufacturing Company Solid dose ballistic projectile
US4657756A (en) * 1980-11-17 1987-04-14 Schering Aktiengesellschaft Microbubble precursors and apparatus for their production and use
US4349530A (en) * 1980-12-11 1982-09-14 The Ohio State University Implants, microbeads, microcapsules, preparation thereof and method of administering a biologically-active substance to an animal
ZA822995B (en) * 1981-05-21 1983-12-28 Wyeth John & Brother Ltd Slow release pharmaceutical composition
IL63220A (en) * 1981-07-01 1985-09-29 Yeda Res & Dev Process for production of polyacrolein microspheres
SE8204244L (sv) * 1982-07-09 1984-01-10 Ulf Schroder Kristalliserad kolhydratsmatris for biologiskt aktiva substanser
US4428926A (en) * 1981-12-18 1984-01-31 Key Pharmaceuticals, Inc. Sustained release propranolol system
US4428925A (en) * 1981-12-18 1984-01-31 Key Pharmaceuticals, Inc. Sustained release glycerol trinitrate
US4479911A (en) * 1982-01-28 1984-10-30 Sandoz, Inc. Process for preparation of microspheres and modification of release rate of core material
US4434153A (en) * 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
US4484923A (en) * 1982-03-25 1984-11-27 Alza Corporation Method for administering immunopotentiator
JPS58209984A (ja) * 1982-05-28 1983-12-07 Japan Synthetic Rubber Co Ltd 粒子状重合体よりなる担体
US4530840A (en) * 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4542025A (en) * 1982-07-29 1985-09-17 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4525339A (en) * 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
AU567155B2 (en) * 1983-04-15 1987-11-12 Damon Biotech Inc. Capsules for releasing core material at constant rate
US4690682A (en) * 1983-04-15 1987-09-01 Damon Biotech, Inc. Sustained release
EP0130162B1 (en) * 1983-06-22 1987-09-09 The Ohio State University Research Foundation Small particle formation and encapsulation
US4608278A (en) * 1983-06-22 1986-08-26 The Ohio State University Research Foundation Small particule formation and encapsulation
GB2160312B (en) * 1984-04-13 1987-09-16 South African Inventions Adjuvant for immunisation
US4764359A (en) * 1984-05-25 1988-08-16 Lemelson Jerome H Drug compositions and their use in treating human or other mammalian patients
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
US4681722A (en) * 1985-10-07 1987-07-21 Owens-Corning Fiberglas Corporation Method of making a lineal structural member
EP0248051A1 (en) * 1985-11-29 1987-12-09 FISONS plc Pharmaceutical composition including sodium cromoglycate
WO1987006129A1 (en) * 1986-04-10 1987-10-22 Daratech Pty. Ltd. Vaccine and implant
PT85521B (pt) * 1986-08-11 1990-06-29 Innovata Biomed Ltd Processo para a preparacao de composicoes farmaceuticas que consistem em microcapsulas
EP0545913B1 (en) * 1986-08-18 1999-02-24 Emisphere Technologies, Inc. Delivery systems for pharmacological agents
IL84167A (en) * 1986-10-24 1991-04-15 Southern Res Inst Oral delivery of bioactive agents to and through the peyer's patch by use of microencapsulation
GB8712176D0 (en) * 1987-05-22 1987-06-24 Cosmas Damian Ltd Drug delivery system

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166800A (en) * 1977-08-25 1979-09-04 Sandoz, Inc. Processes for preparation of microspheres
US4585651A (en) * 1978-10-17 1986-04-29 Stolle Research & Development Corporation Active/passive immunization of the internal female reproductive organs
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4681752A (en) * 1981-06-04 1987-07-21 Laboratorio Farmaceutico Lafarma S.A.S. Capsules containing the active principle of an allergen, and process for their preparation
US4526938A (en) * 1982-04-22 1985-07-02 Imperial Chemical Industries Plc Continuous release formulations

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE112006004066T5 (de) 2006-10-13 2009-08-20 Aleksandr Mettalinovich Tishin Magnetischer Träger und medizinisches Präparat zur kontrollierbaren Zuführung und Freisetzung von Wirkstoffen, Herstellungsverfahren dafür und Behandlungsverfahren unter Verwendung davon

Also Published As

Publication number Publication date
DK175851B1 (da) 2005-04-04
DK222490A (da) 1990-11-16
CN1308937A (zh) 2001-08-22
EP1181929A3 (en) 2003-04-23
JPH03503892A (ja) 1991-08-29
DE68926828D1 (de) 1996-08-22
ES2088890T3 (es) 1996-10-01
IL89602A0 (en) 1989-09-10
IE960647L (en) 1989-09-18
GR3020569T3 (en) 1996-10-31
EP0706792A1 (en) 1996-04-17
CA1340692C (en) 1999-08-03
RU2005104392A (ru) 2006-07-27
WO1989008449A1 (en) 1989-09-21
ATE140386T1 (de) 1996-08-15
CN1043442A (zh) 1990-07-04
EP0333523B1 (en) 1996-07-17
IN169330B (Direct) 1991-09-28
EP1181929A2 (en) 2002-02-27
NZ228376A (en) 1992-05-26
RU2127118C1 (ru) 1999-03-10
DE68929499T2 (de) 2004-09-16
ATE253901T1 (de) 2003-11-15
EP0333523A2 (en) 1989-09-20
KR0126823B1 (ko) 1998-04-01
AU3343389A (en) 1989-10-05
DK222490D0 (da) 1990-09-17
CN1070697C (zh) 2001-09-12
ZA892103B (en) 1990-01-31
EP0333523A3 (en) 1990-01-31
IL89602A (en) 1993-07-08
KR900700084A (ko) 1990-08-11
IE83868B1 (en) 2005-04-20
CN1211080C (zh) 2005-07-20
US5075109A (en) 1991-12-24
DE68929499D1 (de) 2003-12-18
ES2210268T3 (es) 2004-07-01
EP0706792B1 (en) 2003-11-12
AU633483B2 (en) 1993-02-04
DE68926828T2 (de) 1997-01-09
JP2521827B2 (ja) 1996-08-07
HK38897A (en) 1997-04-04

Similar Documents

Publication Publication Date Title
RU2250102C2 (ru) Способ доставки биологически активного соединения на ассоциированную со слизистой оболочкой лимфоретикулярную ткань животного, способ получения композиции и композиция для доставки биологически активного соединения
US5820883A (en) Method for delivering bioactive agents into and through the mucosally-associated lymphoid tissues and controlling their release
Eldridge et al. Biodegradable microspheres: vaccine delivery system for oral immunization
AU607439B2 (en) Method and formulation for orally administering bioactive agents to and through the peyer's patch
IE19960647A1 (en) Method of potentiating an immune response and compositions therefor
Challacombe et al. Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen
Eldridge et al. Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response
AU692440B2 (en) Polymeric mucoadhesives in the delivery of immunogens at mucosal surfaces
DK175960B1 (da) Anvendelse af biokapatible mikrokapsler, sammensætning indeholdende biokapatible mikrokapsler samt fremgangsmåde til fremstilling af en farmaceutisk sammensætning til potensering af et immunrespons
NZ241320A (en) Delivery of bioactive agent to the mucosally associated lymphoreticular tissues of non-human animals
CN1036326A (zh) 用于到达派亚氏淋巴结的口服生物活性剂的制法和配方

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20050317